3-Pyridyl Substituted Aliphatic Cycles as CYP11B2 Inhibitors: Aromaticity Abolishment of the Core Significantly Increased Selectivity over CYP1A2

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Yin, Lina ^a,b   Hu, Qingzhong ^a   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ElexoPharm GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 METHYLIDENE 1,3A,4,5,6,6A HEXAHYDRO PENTALEN 2 YL)PYRIDINE; 3 (DECAHYDRO NAPHTHALEN 2 YL)PYRIDINE; 3 BICYCLO[2.2.1]HEPT 2 EN 2 YL PYRIDINE; 3 BICYCLO[2.2.1]HEPT 2 YL PYRIDINE; 3 CYCLODEC 1 ENYL PYRIDINE; 3 CYCLODECYL PYRIDINE; 3 CYCLODODEC 1 ENYL PYRIDINE; 3 CYCLODODECYL PYRIDINE; 3 CYCLOOCT 1 ENYL PYRIDINE; 3 CYCLOOCTYL PYRIDINE; 5 PYRIDIN 3 YL 1,2,3,3A,4,6A HEXAHYDRO PENTALEN 2 OL; 5 PYRIDIN 3 YL 3,3A,4,6A TETRAHYDRO 1H PENTALEN 2 ONE; 5 PYRIDIN 3 YL CYCLOOCT 4 ENOL; 5 PYRIDIN 3 YL CYCLOOCT 4 ENONE; 5 PYRIDIN 3 YL CYCLOOCTANOL; 5 PYRIDIN 3 YL CYCLOOCTANONE; 5 PYRIDIN 3 YL HEXAHYDRO PENTALEN 2 ONE; 5 PYRIDIN 3 YL OCTAHYDRO PENTALEN 2 OL; 8 METHYL 3 PYRIDIN 3 YL 8 AZA BICYCLO[3.2.1]OCT 2 ENE; 8 METHYL 3 PYRIDIN 3 YL 8 AZA BICYCLO[3.2.1]OCTANE; 8A METHYL 6 PYRIDIN 3 YL 3,7,8,8A TETRAHYDRO 2H NAPHTHALEN 1 ONE; ALDOSTERONE SYNTHASE; CYTOCHROME P450 1A2; CYTOCHROME P450 INHIBITOR; UNCLASSIFIED DRUG;

AROMATIZATION; ARTICLE; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; HYDROGENATION; IC 50; INHIBITION KINETICS; MOLECULAR DOCKING; PROCESS OPTIMIZATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; THERMODYNAMICS;

ALDOSTERONE SYNTHASE; ALGORITHMS; ANDROSTADIENES; AROMATASE INHIBITORS; CATALYTIC DOMAIN; CYTOCHROME P-450 CYP1A2; DRUG DESIGN; ENALAPRIL; FADROZOLE; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; SPIRONOLACTONE; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE;

EID: 84868317925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048048     Document Type: Article

References (45)

1. Lijnen P, Petrov V, (2000) Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 32: 865-879.
2. Weber KT, Brilla CG, (1991) Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865.
3. Sato A, Saruta T, (2001) Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29: 13-21.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709-717.
5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Eng J Med 348: 1309-1321.
6. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, et al. (2005) Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 46: 701-706.
7. Kawamoto T, Mitsuuchi Y, Toda K, Yokoyama Y, Miyahara K, et al. (1992) Role of steroid 11β-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci U S A 89: 1458-1462.
8. Hartmann RW, (1994) Selective inhibition of steroidogenic P450 enzymes: current status and future perspectives. Eur J Pharm Sci 2: 15-16.
9. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, et al. (2005) Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111: 3087-3094.
10. Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, et al. (2008) Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 29: 2171-2179.
11. Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, et al. (2005) Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem 48: 6632-6642.
12. Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, et al. (2006) Synthesis and evaluation of heteroaryl-substituted dihydro-naphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem 49: 2222-2231.
13. Ulmschneider S, Müller-Vieira U, Klein CD, Antes I, Lengauer T, et al. (2005) Synthesis and evaluation of (pyridylmethylene)tetrahydro-naphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem 48: 1563-1575.
14. Ulmschneider S, Müller-Vieira U, Mitrenga M, Hartmann RW, Oberwinkler-Marchais S, et al. (2005) Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone Synthase. J Med Chem 48: 1796-1805.
15. Lucas S, Heim R, Ries C, Schewe KE, Birk B, et al. (2008) In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. J Med Chem 51: 8077-8087.
16. Lucas S, Heim R, Negri M, Antes I, Ries C, et al. (2008) Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem 51: 6138-6149.
17. Heim R, Lucas S, Grombein CM, Ries C, Schewe KE, et al. (2008) Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene- type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity. J Med Chem 51: 5064-5074.
18. Lucas S, Negri M, Heim R, Zimmer C, Hartmann RW, (2011) Fine-tuning the selectivity of aldosterone synthase inhibitors: insights from studies from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinoline-4-one derivatives. J Med Chem 54: 2307-2319.
19. Hu Q, Yin L, Hartmann RW, (2012) Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer. J Med Chem 55: 7080-7089.
20. Hartmann RW, Bayer H, Grün G, (1994) Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans, and tetralins. J Med Chem 37: 1275-81.
21. Gobbi S, Cavalli A, Rampa A, Belluti F, Piazzi L, et al. (2006) Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem 49: 4777-4780.
22. Cavalli A, Bisi A, Bertucci C, Rosini C, Paluszcak A, et al. (2005) Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem 48: 7282-7289.
23. Gobbi S, Cavalli A, Negri M, Schewe KE, Belluti F, et al. (2007) Imidazolylmethylbenzophenones as highly potent aromatase inhibitors. J Med Chem 50: 3420-3422.
24. Leze MP, Le Borgne M, Pinson P, Palusczak A, Duflos M, (2006) Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors. Bioorg Med Chem Lett 16: 1134-1137.
25. Marchand P, Le Borgne M, Palzer M, Le Baut G, Hartmann RW, (2003) Preparation and pharmacological profile of 7-(α-Azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors. Bioorg Med Chem Lett 13: 1553-1555.
26. Abadi AH, Abou-Seri SM, Hu Q, Negri M, Hartmann RW (2012) Synthesis and biological evaluation of imidazolylmethylacridones as cytochrome P-450 enzymes inhibitors. MedChemComm 3, 663-666.
27. Al-Soud YA, Heydel M, Hartmann RW, (2011) Design and synthesis of 1,3,5-trisubstituted 1,2,4-triazoles as CYP enzyme inhibitors. Tetrahedron Lett 52: 6372-6375.
28. Hille UE, Zimmer C, Vock CA, Hartmann RW, (2011) Discovery of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases. ACS Med Chem Lett 2: 2-6.
29. Hille UE, Zimmer C, Haupenthal J, Hartmann RW, (2011) Optimization of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases. ACS Med Chem Lett 2: 559-564.
30. Yin L, Lucas S, Maurer F, Kazmaier U, Hu Q, et al. (2012) Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 Inhibitors for the treatment of Cushing's syndrome. J Med Chem 55: 6629-6633.
31. Hu Q, Negri M, Olgen S, Hartmann RW, (2010) The role of fluorine substitution in biphenyl methylene imidazole type CYP17 inhibitors for the treatment of prostate carcinoma. ChemMedChem 5: 899-910.
32. Hu Q, Jagusch C, Hille UE, Haupenthal J, Hartmann RW, (2010) Replacement of imidazolyl by pyridyl in biphenyl methylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer. J Med Chem 53: 5749-5758.
33. Hu Q, Yin L, Jagusch C, Hille UE, Hartmann RW, (2010) Isopropylidene substitution increases activity and selectivity of biphenyl methylene 4-pyridine type CYP17 inhibitors. J Med Chem 53: 5049-5053.
34. Hu Q, Negri M, Jahn-Hoffmann K, Zhuang Y, Olgen S, et al. (2008) Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17)-Part II: Core rigidification and influence of substituents at the methylene bridge. Bioorg Med Chem 16: 7715-7727.
35. Hille UE, Hu Q, Vock C, Negri M, Bartels M, et al. (2009) W. Novel CYP17 inhibitors: Synthesis, biological evaluation, structure-activity relationships and modeling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls. Eur J Med Chem 44: 2765-2775.
36. Pinto-Bazurco Mendieta MAE, Negri M, Hu Q, Hille UE, Jagusch C, et al. (2008) CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modeling. Arch Pharm (Weinheim, Ger.) 341: 597-609.
37. Hille UE, Hu Q, Pinto-Bazurco Mendieta MAE, Bartels M, Vock CA, et al. (2009) Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: Combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile. C R Chim 12, 1117-1126.
38. Jagusch C, Negri M, Hille UE, Hu Q, Bartels M, et al. (2008) Synthesis, biological evaluation and molecular modeling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17) - Part I: heterocyclic modifications of the core structure. Bioorg Med Chem 16: 1992-2010.
39. Leroux F, Hutschenreuter TU, Charriere C, Scopelliti R, Hartmann RW, (2003) N-(4-biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: metabolic robustness due to fluorine substitution? Helv Chim Acta 86: 2671-2686.
40. Pinto-Bazurco Mendieta MAE, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, et al. (2008) Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: Novel CYP17 inhibitors for the treatment of prostate cancer. J Med Chem 51: 5009-5018.
41. Hartmann RW, Frotscher M, Ledergerber D, Waechter GA, Gruen GL, et al. (1996) Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17 and P450 TxA2. Arch Pharm (Weinheim, Ger.) 329: 251-261.
42. Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW, (2003) Effects of novel 17α-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol 84: 555-562.
43. Korhonen LE, Rahnasto M, Mähönen NJ, Wittekindt C, Poso A, et al. (2005) Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem 48: 3808-3815.
44. Ehmer PB, Bureik M, Bernhardt R, Müller U, Hartmann RW, (2002) Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): Screening in fission yeast and evaluation of selectivity in V79 cells. J Steroid Biochem Mol Biol 81: 173-179.
45. Roumen L, Peeters JW, Emmen JMA, Beugels IPE, Custers EMG, et al. (2010) Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem 53: 1712-1725.